1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Kidney Disease (Chronic Renal Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Chronic Kidney Disease (Chronic Renal Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Chronic Kidney Disease (Chronic Renal Failure) Report is to understand the market and pipeline status of the drugs around the Chronic Kidney Disease (Chronic Renal Failure) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Kidney Disease (Chronic Renal Failure). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the marketed products under prescription for Chronic Kidney Disease (Chronic Renal Failure), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Chronic Kidney Disease (Chronic Renal Failure) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Chronic Kidney Disease (Chronic Renal Failure) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Chronic Kidney Disease (Chronic Renal Failure) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Chronic Kidney Disease (Chronic Renal Failure) drugs.
- Coverage of Chronic Kidney Disease (Chronic Renal Failure) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Chronic Kidney Disease (Chronic Renal Failure) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Chronic Kidney Disease (Chronic Renal Failure).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Chronic Kidney Disease (Chronic Renal Failure).
- API intelligence over marketed drugs forChronic Kidney Disease (Chronic Renal Failure)and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Chronic Kidney Disease (Chronic Renal Failure).
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Chronic Kidney Disease (Chronic Renal Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Chronic Kidney Disease (Chronic Renal Failure)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Chronic Kidney Disease (Chronic Renal Failure)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Chronic Kidney Disease (Chronic Renal Failure)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, (Year), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, Europe by Country, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, India by State, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, China by Province, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers by Geography 2016
- Chronic Kidney Disease (Chronic Renal Failure) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Chronic Kidney Disease (Chronic Renal Failure), 2016
- Discontinued Drugs for Chronic Kidney Disease (Chronic Renal Failure), 2016

List of Figures

- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, US, (Year), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, Europe by Country, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, India by State, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers, China by Province, 2016
- Chronic Kidney Disease (Chronic Renal Failure) Drugs, API Manufacturers by Geography 2016
- Chronic Kidney Disease (Chronic Renal Failure) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Kidney Disease (Chronic Renal Failure) Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Lupus Nephritis - Epidemiology Forecast To 2023

Lupus Nephritis - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Lupus Nephritis - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Lupus Nephritis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). ...

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • August 2016
  • by Global Data

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016" provides an overview ...

 Lupus Nephritis-Pipeline Insights, 2016

Lupus Nephritis-Pipeline Insights, 2016

  • $ 1250
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “ Lupus Nephritis-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Lupus Nephritis. The DelveInsight’sReport ...

Systematic Lupus Erythematosus

April 2016 $ 5000

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.